Brokers Issue Forecasts for Vigil Neuroscience, Inc.’s Q1 2024 Earnings (NASDAQ:VIGL)

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Stock analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Vigil Neuroscience in a research report issued to clients and investors on Wednesday, March 27th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.58) per share for the quarter. HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Vigil Neuroscience’s Q3 2024 earnings at ($0.58) EPS.

Separately, Morgan Stanley cut Vigil Neuroscience from an “equal weight” rating to an “underweight” rating and dropped their price objective for the stock from $13.00 to $4.00 in a report on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.40.

Vigil Neuroscience Price Performance

Shares of VIGL stock opened at $3.20 on Thursday. The stock has a market capitalization of $114.82 million, a PE ratio of -1.50 and a beta of 1.80. Vigil Neuroscience has a 1-year low of $2.53 and a 1-year high of $11.11. The business has a 50-day moving average of $3.06 and a 200 day moving average of $4.32.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in VIGL. Bank of New York Mellon Corp purchased a new position in shares of Vigil Neuroscience in the 1st quarter valued at approximately $94,000. Citigroup Inc. bought a new position in Vigil Neuroscience during the 1st quarter valued at approximately $451,000. BlackRock Inc. bought a new position in Vigil Neuroscience during the 1st quarter valued at approximately $2,135,000. Vanguard Group Inc. bought a new position in Vigil Neuroscience during the 1st quarter valued at approximately $2,708,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Vigil Neuroscience during the 1st quarter valued at approximately $135,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.